Released: March 28, 2022
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Tick-Borne Disease Research Program (TBDRP)
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
The FY22 Defense Appropriations Act provides funding for the TBDRP to support innovative, high-impact tick-borne disease research. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The TBDRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY22 TBDRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applicants to the FY22 TBDRP funding opportunities must be relevant to at least one of the following Focus Areas. Applicants are particularly encouraged to submit applications focused on tick-borne diseases (TBDs) and conditions endemic to the U.S., and/or involving patients with persistent Lyme disease. The proposed research must be focused on directly impacting human health and diseases/conditions that affect the U.S. military (active duty or veteran), their beneficiaries, or the American public.
- Prevention (Idea Development Award only)
- Drugs, antibodies, vaccines, or other novel approaches that can be administered and/or utilized prophylactically to prevent human TBDs and conditions prevalent in the U.S. or that address multiple pathogens
- Identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions that are safe and non-toxic to non-target species
- Pathogenesis (Idea Development Award only)
- Pathogenesis of persistent clinical manifestations associated with Lyme disease
- Immune evasion and/or tolerance of tick-borne (TB) pathogens (Lyme and/or other TBDs)
- TB infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, or pathogen synergy and competition
- Pathogenesis of mammalian meat allergy (allergic response to galactose-alpha-1,3-galactose [alpha gal])
- Understanding the role of TBDs on maternal health and adverse birth outcomes, including maternal-fetal transmission
- Treatment (Therapeutic/Diagnostic Idea Award only)
- Novel preclinical therapeutic strategies for TB pathogens, Lyme disease, and/or other TBDs with priority given to those in the U.S.
- Potential treatments designed to mitigate development of long-term sequelae following infection
- Repurposing Food and Drug Administration (FDA)-approved drugs for off-label indication in preclinical evaluation for use in TBDs
- Diagnosis (Therapeutic/Diagnostic Idea Award only)
- Priority given to development of direct detection diagnostic assays for agents of Lyme disease and/or other TBDs
- Diagnostic biomarker panel for Lyme disease and/or other TBDs that distinguishes TB infection from other febrile illnesses
- Approaches capable of distinguishing active infection and previous exposure and/or monitoring response to treatment
- Innovative approaches that provide diagnosis for a single or multiple TB infections
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Idea Development Award (IDA)|| IDA: Independent investigators at or above the level of Assistant Professor (or equivalent)
IDA – Career Development Option:
|Therapeutic/ Diagnostic Idea Award (TDIA)|| TDIA: Independent investigators at or above the level of Assistant Professor (or equivalent)
TDIA – Career Development Option:
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunities are released. For email notification when funding opportunities are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the TBDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Monday, March 28, 2022